Merck & Co., Inc. (MRK)
2 Reasons to Sell Merck Stock and 1 Reason to Buy
There is plenty to like about Merck (MRK -0.25%). It is one of the largest pharmaceutical companies and the owner of the world's current best-selling drug, cancer medicine Keytruda.
Merck (MRK) Rises Yet Lags Behind Market: Some Facts Worth Knowing
Merck (MRK) closed the most recent trading day at $99.45, moving +0.08% from the previous trading session.
Merck to discontinue drug for bacterial infection
Merck will discontinue its drug for a bacterial infection that can lead to fatal diarrhea, the U.S. Food and Drug Administration's website showed on Monday.
Merck: A Low-Hanging Fruit To Pick
Merck, a leading global pharmaceutical company that produces a range of medicines, vaccines, and animal healthcare products, is now a $258 billion (by market cap) healthcare behemoth. The US is the company's largest market, accounting for approximately 47% of worldwide sales. Merck has started showing signs of sustained growth starting from right about FY 2020, as Keytruda is growing way faster than 5% annually.
Is Merck the Next Big Weight-Loss Stock?
Watch out, Eli Lilly and Novo Nordisk. Merck (MRK -1.48%) is hungrily looking to take a bite out of the weight-loss drugs market.
MRK's Pivotal Study on Two-Drug, Once-Daily HIV Pill Meets Goals
Merck posts positive data from two phase III studies evaluating a two-drug, single-tablet regimen of doravirine/islatravir in adults with HIV-1 infection.
Merck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching Merck (MRK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Want to Collect a Dividend Every Month? Invest in These 3 High-Yielding Income Stocks
Collecting dividend income on a recurring basis can help strengthen your financial position and be a way for you to be less dependent on other sources of cash flow. The one downside is that many dividend stocks only pay on a quarterly basis, which means that you'll often be waiting multiple months before the next dividend payment.
Stock Of The Day: Where Does The Merck Downtrend End?
Shares of Merck & Co., Inc. MRK are trading flat on Thursday, but remain in a downtrend.
Merck: Healthcare Pharma Giant: 3.2% Yield, 9.3% 5-Year Dividend Growth, Buy Time
Merck & Co., a global pharmaceutical leader, focuses on oncology, immunology, and vaccines, with strong revenue from Keytruda and Gardasil despite challenges in China. Strategic acquisitions and partnerships, including Acceleron, Prometheus, and Daiichi Sankyo, bolster Merck's drug pipeline and expand its oncology and cardiovascular portfolios. Merck's robust R&D efforts and wide moat, supported by a strong dividend yield and A+ S&P credit rating, make it a compelling buy.
Merck's HIV treatment meets main goal of two late-stage studies
Merck said on Thursday its experimental drug combination to treat some adults with HIV-1 infection met the main goal of two late-stage studies.
Merck's weight-loss pill deal: what it means for Eli Lilly
Merck & Co Inc (NYSE: MRK) is in focus this morning after announcing a $2.0 billion deal with Hansoh Pharma. The said agreement wins it rights to HS-10535 – an experimental weight-loss pill (oral) developed by the Chinese drugmaker.
